Phreesia, Inc. (NYSE:PHR) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Phreesia, Inc. (NYSE:PHR) have received a consensus recommendation of “Moderate Buy” from the nineteen brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and seventeen have given a buy rating to the company. The average twelve-month price target among brokerages that have covered the stock in the last year is $29.4118.

Several research analysts recently commented on PHR shares. Robert W. Baird dropped their target price on shares of Phreesia from $31.00 to $25.00 and set an “outperform” rating on the stock in a report on Wednesday, December 10th. Wall Street Zen cut Phreesia from a “strong-buy” rating to a “buy” rating in a research report on Sunday, February 8th. Zacks Research lowered Phreesia from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 6th. Royal Bank Of Canada started coverage on Phreesia in a research report on Friday, January 9th. They issued a “moderate buy” rating and a $26.00 price objective for the company. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Phreesia in a research report on Wednesday, January 28th.

Phreesia Stock Up 4.0%

PHR opened at $12.58 on Friday. The firm has a market cap of $758.45 million, a P/E ratio of -125.79 and a beta of 0.65. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.44 and a current ratio of 2.44. The business has a 50 day moving average price of $15.21 and a 200 day moving average price of $21.03. Phreesia has a twelve month low of $11.57 and a twelve month high of $32.76.

Phreesia (NYSE:PHR) last released its quarterly earnings results on Monday, December 8th. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.11. The company had revenue of $120.33 million for the quarter, compared to analyst estimates of $119.98 million. Phreesia had a negative net margin of 1.16% and a negative return on equity of 1.31%. The company’s quarterly revenue was up 12.7% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.25) earnings per share. Research analysts forecast that Phreesia will post -1.1 EPS for the current year.

Insider Buying and Selling at Phreesia

In related news, SVP Amy Beth Vanduyn sold 2,202 shares of the business’s stock in a transaction dated Friday, January 16th. The stock was sold at an average price of $16.36, for a total transaction of $36,024.72. Following the transaction, the senior vice president directly owned 157,349 shares in the company, valued at $2,574,229.64. The trade was a 1.38% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, insider David Linetsky sold 6,038 shares of the firm’s stock in a transaction that occurred on Friday, January 16th. The stock was sold at an average price of $16.36, for a total value of $98,781.68. Following the completion of the sale, the insider owned 223,942 shares of the company’s stock, valued at $3,663,691.12. This represents a 2.63% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 60,766 shares of company stock valued at $1,013,817 over the last quarter. Company insiders own 5.50% of the company’s stock.

Institutional Investors Weigh In On Phreesia

Institutional investors and hedge funds have recently bought and sold shares of the business. Federated Hermes Inc. bought a new position in shares of Phreesia during the 3rd quarter worth about $32,000. Van ECK Associates Corp lifted its stake in Phreesia by 78.7% during the fourth quarter. Van ECK Associates Corp now owns 2,502 shares of the company’s stock worth $42,000 after purchasing an additional 1,102 shares during the period. Asset Management One Co. Ltd. bought a new position in Phreesia during the third quarter worth about $45,000. KBC Group NV boosted its holdings in Phreesia by 83.4% during the fourth quarter. KBC Group NV now owns 3,449 shares of the company’s stock valued at $58,000 after purchasing an additional 1,568 shares in the last quarter. Finally, Garner Asset Management Corp bought a new stake in shares of Phreesia in the 4th quarter valued at approximately $81,000. Institutional investors own 92.10% of the company’s stock.

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.